Artificial Intelligence in Molecular Imaging: Predicting Parkinson's Risk in REM Sleep Behavior Disorder

NCT06629207 · Insel Gruppe AG, University Hospital Bern

Recruiting

In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title

Artificial Intelligence on Molecular Imaging to Predict the Risks of Parkinson's Disease for Patients With Rapid Eye Movement Sleep Behavior Disorder

About this study

The study aims to systematically document the course of REM sleep behavior disorder (RBD) and investigate possible clinical and imaging biomarkers for disease progression and conversion risk to Parkinson's disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). The study will use artificial intelligence to analyze imaging and develop a reliable method to predict and stratify patients approaching conversion to overt a-synucleinopathy. Participants will be clinically evaluated and 2 imaging procedures will be done.

Eligibility criteria

Inclusion Criteria: 1. Confirmed clinical iRBD diagnosis by movement disorder specialists according to the International Classification of Sleep Disorders 2. Written informed consent Exclusion Criteria: 1. Known diagnosis of PD or other neurodegenerative disorder 2. Unequivocal signs of parkinsonism on examination 3. Narcolepsy or other known causes of RBD 4. Moderate to severe obstructive sleep apnea 5. Abnormal neurological or MRI examination

Study design

Enrollment target: 20 participants

Allocation: na

Masking: none

Age groups: adult, older_adult

Timeline

Starts: 2024-10-07

Estimated completion: 2026-08-01

Last updated: 2024-11-08

Interventions

Device: PET/CT with 18-FDGDevice: SPECT : 123 I-FP-CIT (DATSCAN)Device: MRI

Primary outcomes

• Assessment of Deep Learning Model Accuracy in Predicting Neurodegenerative Conversion in isolated REM sleep behavior disorder (iRBD) through Early Biomarker Detection (From enrollment to end of follow-up period, expected to be 48 months)

Sponsor

Insel Gruppe AG, University Hospital Bern · other

Contacts & investigators

ContactAxel Rominger, Prof. Dr. med. · contact · axel.rominger@insel.ch · +41 316322610

ContactFranziska Strunz, PhD · contact · studies.nuk@insel.ch · +41 316643022

InvestigatorKuanggyu Shi, Prof. Dr. ing. · principal_investigator, University Bern, Inselspital, Center for Artificial Intelligence in Medicine

All locations (1)

Inselspital, University Clinic for Nuclear MedicineRecruiting

Bern, Switzerland

View on ClinicalTrials.gov ↗Find similar trials